ImmuneOnco plans to release clinical data for AXN-2510/IMM2510 in NSCLC in 2025, initiating trials in China and the U.S. Instil Bio, Inc. announced plans for the clinical development of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback